Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors - PubMed
5 hours ago
- #solid tumor immunotherapy
- #cancer therapeutics
- #T cell engagers
- T cell engagers (TCEs) redirect T cells to tumor cells, enhancing antitumor immunity, and are expanding from hematologic to solid tumors.
- Recent approval of tarlatamab for small cell lung cancer highlights progress, but efficacy in solid tumors faces challenges like the immunosuppressive tumor microenvironment and toxicity.
- Advances include improved molecular designs, biomarker-guided patient selection, and combination therapies to overcome resistance and boost outcomes.
- Next-generation approaches involve engagers that redirect other immune cells, aiming for more precise and effective solid tumor treatments.